Yes, you can still get pneumonia after vaccination. No pneumonia vaccine prevents every case. The vaccines cut the risk of the most dangerous bacterial types and their worst outcomes, but they do not create a force field. Pneumococcus has more than 100 serotypes, and the vaccines target only the ones most likely to cause severe invasive disease. Viruses cause a large share of pneumonia and are untouched by bacterial vaccines. Protection also varies by serotype, age, health status, and time since vaccination. So a vaccinated person can develop pneumonia from a non-vaccine strain, a virus, or another bacterium entirely.
This is not a failure of vaccination. It is how these vaccines are designed to work.
What the vaccines actually target
Pneumococcal vaccines do not block infection at the doorway. They train the immune system to recognize the sugar coating, called a polysaccharide capsule, that surrounds Streptococcus pneumoniae. That capsule is the bacterium's armor, and it differs across serotypes. The vaccines contain purified capsular sugars from selected serotypes, either alone or attached to a carrier protein.
The conjugate design matters. Plain polysaccharide vaccines trigger B cells without much T-cell help, so the response fades and does not reliably train immune memory in young children. Conjugate vaccines link the sugar to a protein, which recruits T cells. That produces stronger antibody levels and, critically, memory B cells that can respond years later. This is why conjugate vaccines work in infants and why they reduce nasopharyngeal carriage, not just disease.
Protection is serotype-specific. Antibodies against the sugars in the vaccine neutralize those serotypes. A serotype not in the vaccine is invisible to that immunity. The vaccine also reduces how often vaccinated people carry pneumococcus in the nose and throat, which slows transmission to unvaccinated people. That herd effect is one reason invasive pneumococcal disease fell in all age groups after childhood conjugate vaccination began. A pneumococcal vaccine is a targeted shield, not a general antimicrobial.
How much protection, and against what
The numbers depend on which vaccine, which outcome, and which population. The table below compares the main products in use in the United States.
| Vaccine | Serotypes covered | Who it is for | Key protection data |
|---|---|---|---|
| PCV15 (Vaxneuvance) | 15 | Infants and children; adults 65+ and younger adults with risk conditions | Noninferior to PCV13 for shared serotypes in adults; adds 22F and 33F |
| PCV20 (Prevnar 20) | 20 | Infants and children; adults 65+ and younger adults with risk conditions | Noninferior to PCV13 for shared serotypes; covers 7 more serotypes |
| PCV21 (Capvaxive) | 21 | Adults only | Covers serotypes responsible for about 83% of invasive disease in adults 50+ |
| PPSV23 (Pneumovax 23) | 23 (plain polysaccharide) | Adults with risk conditions; selected children | Older product; weaker memory response; used in specific sequences |
Against invasive pneumococcal disease, the outcome these vaccines were licensed on, effectiveness in adults is generally in the range of roughly 50 to 75 percent depending on serotype match and population. Against pneumonia without bacteremia, which is far more common and harder to diagnose, protection is lower and more variable. A meta-analysis in adults found conjugate vaccines reduced vaccine-type pneumococcal pneumonia but had limited and inconsistent effect on all-cause pneumonia. That gap is expected: most pneumonia is not vaccine-type pneumococcus.
For children, the impact has been large. After conjugate vaccines were introduced, invasive pneumococcal disease in young children fell by roughly 80 percent or more for vaccine serotypes. All-cause pneumonia hospitalizations also declined, though by a smaller margin. Plain language: the vaccine removes the most lethal strains but leaves many other causes in play.
The timeline of protection
Immunity is not instant, and it is not permanent. The table below shows the typical course.
| Stage | What happens | Approximate timing |
|---|---|---|
| Vaccination | Injection of capsular sugars with protein carrier | Day 0 |
| Early antibody rise | Initial IgM and then IgG response | 1 to 2 weeks |
| Peak response | Antibody levels peak for vaccine serotypes | 4 to 6 weeks |
| Established memory | Memory B cells and T-cell help consolidate | 1 to 3 months |
| Waning | Antibody levels drift down over years | Gradual, years |
| Booster or next vaccine | Re-exposure restores and broadens response | Per schedule |
This timeline explains two counterintuitive observations. First, protection is incomplete in the first weeks after a dose, so pneumonia can occur right after vaccination without meaning the vaccine failed. Second, protection erodes over time, which is why adults over 65 and people with risk conditions may receive later doses. A vaccinated person sick with pneumonia months or years after a dose may simply be past peak antibody levels for some serotypes.
Edge cases where protection is weakest
Certain groups get less from the vaccine, and understanding why explains most breakthrough cases.
Adults over 65: immune senescence reduces the magnitude and durability of antibody responses, so effectiveness against pneumonia is lower than in younger adults. People with weakened immunity: conditions such as HIV, cancer treatment, transplant, or long-term steroid use blunt vaccine responses. Asplenia or complement disorders: people without a functioning spleen or complement system are highly vulnerable to encapsulated bacteria, and vaccines only partly compensate. Chronic lung disease: structural lung damage and impaired clearance raise baseline pneumonia risk regardless of vaccine status. Very young infants: protection depends on the schedule being completed, and maternal antibodies can blunt early responses.
There is a counterintuitive detail here. People at highest risk of pneumococcal disease are often the same people who respond least to the vaccine. The vaccine reduces risk in these groups, but it cannot equalize it. A professional caveat follows: for immunocompromised patients, the vaccine's value is in lowering the probability of severe invasive disease, not in preventing every respiratory infection.
Red flags that need prompt attention
Vaccination status does not change the urgency of certain symptoms. Seek care promptly for:
Difficulty breathing or rapid breathing at rest. Chest pain that worsens with breathing, or coughing up blood. High fever with confusion, especially in an older adult. A bluish tint to lips, or oxygen saturation that is low for the person's baseline. Symptoms that worsen after initial improvement, suggesting secondary bacterial pneumonia after a viral illness.
Where vaccines fall short, and why
The biggest reason is that pneumonia is a syndrome, not one disease. It has bacterial, viral, and fungal causes. Pneumococcal vaccines target one bacterial species and, within it, only selected serotypes. Viral pneumonias from influenza, respiratory syncytial virus, and coronaviruses are unaffected by pneumococcal vaccination.
Serotype replacement is the second reason. When vaccines suppress the covered serotypes, other serotypes can move into the vacated niche. Carriage of non-vaccine serotypes rises, and some of that translates into non-vaccine-type disease. This is why vaccine formulas keep expanding, from 7 to 13 to 15, 20, and 21 serotypes. It is also why a person vaccinated with an older product may carry little protection against serotypes added later.
Misconceptions deserve direct correction. One is that the pneumonia shot covers all pneumonia; it does not, and it does not cover viruses. Another is that breakthrough pneumonia means the vaccine is useless; it means the vaccine did not cover that cause, which is expected for non-vaccine strains and viruses. A third is that one dose lasts forever; antibodies wane, and recommendations for adults include revaccination based on age and risk. A fourth is that the vaccine prevents colds and bronchitis; it is not designed to, and most such illnesses are viral.
Practical actions for vaccinated people
The vaccine is one layer of protection. These steps complement it.
Get the influenza vaccine every season and other recommended adult vaccines. Influenza infection predisposes to secondary bacterial pneumonia. Know your risk category and ask a clinician whether you need a pneumococcal vaccine beyond childhood, especially at age 65 or with chronic conditions. Do not delay care for pneumonia symptoms because you were vaccinated. The vaccines do not rule out pneumonia. Avoid tobacco smoke and treat chronic lung disease, which raises baseline risk. Practice hand hygiene and avoid close contact with people who have active respiratory infections.
Limitations of the evidence
The evidence base has real gaps. Effectiveness estimates come largely from invasive disease, because pneumonia without bacteremia is hard to confirm in trials. All-cause pneumonia endpoints are noisy, which is why some studies show modest effects. Serotype data depend on surveillance systems that vary by country. Vaccine formulas and recommendations change as serotypes shift, so a figure from one era may not apply now. And protection in the frailest patients is understudied, leaving clinicians to extrapolate from broader trials. The honest position is that these vaccines meaningfully reduce severe pneumococcal disease and save lives, while leaving a large share of pneumonia risk untouched by design.